Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus (NASDAQ:TARS) announced that management will participate in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference/b] on June 2 at 8:00 a.m. PT / 11:00 a.m. ET and the on June 3 at 8:40 a.m. PT / 11:40 a.m. ET.
Live webcasts, details, and limited-time replays will be available in the events section of the Tarsus website.
Tarsus (NASDAQ:TARS) announced a partnership with John Cena to raise awareness of Demodex blepharitis, a common eyelid disease affecting about 25 million Americans. The campaign highlights symptoms such as redness, itching and crusting, and promotes regular eye exams and treatment options.
Cena shares his experience being diagnosed with Demodex blepharitis and treated with XDEMVY (lotilaner ophthalmic solution) 0.25%, described as the first and only FDA-approved treatment that directly targets and kills the mites causing the disease.
Tarsus (NASDAQ: TARS) announced management will participate in three investor conferences in May 2026: Bank of America Health Care Conference on May 12 (3:40 p.m. PT / 6:40 p.m. ET), H.C. Wainwright BioConnect on May 19 (8:00 a.m. PT / 11:00 a.m. ET), and Stifel Virtual Ophthalmology Forum on May 26 (12:30 p.m. PT / 3:30 p.m. ET).
Live webcasts and additional details are available on the company's events page. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported Q1 2026 XDEMVY net product sales of $145.4M, up >85% year-over-year, and reaffirmed full-year 2026 XDEMVY guidance of $670–700M with peak sales potential exceeding $2 billion. Cash and marketable securities totaled $388.7M. The company initiated a Phase 2 trial for TP-05 and expects multiple topline readouts in H1 2027.
Management will host a conference call on May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET.
Tarsus Pharmaceuticals (NASDAQ: TARS) will report first quarter 2026 financial results on Wednesday, May 6, 2026 with a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. A recorded version will be posted to the company's website shortly after the call and archived for approximately 90 days.
Tarsus (NASDAQ: TARS) dosed the first participant in Calliope, a randomized, double-blind Phase 2 trial of TP-05 (lotilaner) to evaluate safety, tolerability and pharmacokinetics for potential prevention of Lyme disease by killing infected ticks before transmission.
Calliope will enroll ~700 healthy adults across U.S. endemic regions, aims to complete enrollment during the 2026 tick season, and expects topline results in H1 2027. Prior Phase 2a Carpo showed >90% tick kill within 24 hours and statistically significant benefit versus placebo (p<0.001); preclinical mouse studies showed 90% efficacy versus 0% in controls.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced a $15 million milestone payment after Grand Pharmaceutical Group obtained NMPA approval in China for TP-03 (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis. The approval covers the Greater China region and triggers agreed patent-related and regulatory milestones.
Under the partnership, Tarsus may receive additional payments for regulatory milestones, China sales thresholds, and tiered royalties tied to TP-03 commercial performance in the region.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced management will participate in upcoming investor conferences in early March 2026. Presentations are scheduled at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:30 a.m. PT / 2:30 p.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 9:30 a.m. PT / 12:30 p.m. ET.
Live webcasts and event details are available on the company website. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported full-year 2025 net product sales for XDEMVY of $451.4 million (up >150% YoY) and Q4 sales of $151.7 million. The company delivered ~400,000 bottles in 2025, maintains >90% payer coverage, and ended Year‑end cash of $417.3 million. Pipeline progress includes a Phase 2 start for TP-04 and a planned TP-05 Phase 2 in Q2 2026.
Management expects XDEMVY peak sales potential >$2 billion and noted ongoing regulatory paths in Europe, Japan, and Greater China.
Tarsus Pharmaceuticals (NASDAQ: TARS) appointed David E. I. Pyott, former Allergan CEO, to its Board of Directors on February 18, 2026.
Mr. Pyott brings 17 years of leadership at Allergan, growing sales from about $1 billion to more than $7 billion, and experience across R&D, product development and commercial execution to support XDEMVY and the pipeline.